VVOS News and Press, Vivos Therapeutics Inc. From 11/23/23

2023-11-23 06:45:55 ET More on Vivos Therapeutics Vivos Therapeutics, Inc. (VVOS) Q3 2023 Earnings Call Transcript Vivos Therapeutics prices $4M public offering Vivos Therapeutics announces 1-for-25 reverse stock split Seeking Alpha’s Quant Rating on V...

2023-11-17 19:12:10 ET Vivos Therapeutics, Inc. (VVOS) Q3 2023 Earnings Conference Call November 14, 2023 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman and Chief Executive Officer Brad Amman - Chief Financial O...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, is reporting financial results and operat...

2023-11-14 16:18:49 ET More on Vivos Therapeutics Vivos Therapeutics prices $4M public offering Vivos Therapeutics announces 1-for-25 reverse stock split Seeking Alpha’s Quant Rating on Vivos Therapeutics Historical earnings data for Vivos Therapeutics...

Operating Expenses Decreased 32% Year Over Year and 19% Sequentially as Cost Cutting Measures Take Hold New Strategic Relationships, Including U.S. Nationwide Distribution Agreement with Lincare, Expected to Add Potentially Significant New Revenue Opportunities Management to Hos...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

Vivos Therapeutics Inc. (VVOS) is expected to report $-3.25 for Q3 2023

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, is planning to release its Q3 2023 financ...

LITTLETON, Colo., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) , a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-mo...

--News Direct-- Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive to share news the company has signed a nationwide distribution agreement in the United States with Lincare, a prominent supplier of in-home respiratory therapy products and services catering to approx...